{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:40:12Z","timestamp":1789170012757,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Flinders Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jprot.2018.09.018","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T11:57:21Z","timestamp":1538827041000},"page":"374-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma"],"prefix":"10.1016","volume":"192","author":[{"given":"Reuben","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Pulford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Elliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6183-2797","authenticated-orcid":false,"given":"Lauren A.","family":"Thurgood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jprot.2018.09.018_bb0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2559.1997.5460776.x","article-title":"Pathology of malignant mesothelioma","volume":"30","author":"Attanoos","year":"1997","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.jprot.2018.09.018_bb0010","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<549::AID-CNCR18>3.0.CO;2-4","article-title":"Mesothelioma, asbestos, and reported history of cancer in first-degree relatives","volume":"77","author":"Heineman","year":"1996","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jprot.2018.09.018_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/jes.2016.18","article-title":"Mortality from asbestos-associated disease in Libby, Montana 1979-2011","volume":"27","author":"Naik","year":"2017","journal-title":"J. Expo. Sci. Environ. Epidemiol."},{"issue":"3","key":"10.1016\/j.jprot.2018.09.018_bb0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2486\/indhealth.45.379","article-title":"Malignant mesothelioma: global incidence and relationship with asbestos","volume":"45","author":"Bianchi","year":"2007","journal-title":"Ind. Health"},{"issue":"5","key":"10.1016\/j.jprot.2018.09.018_bb0025","article-title":"Asbestos-related lung disease","volume":"75","author":"O'Reilly","year":"2007","journal-title":"Am. Fam. Physician"},{"issue":"5","key":"10.1016\/j.jprot.2018.09.018_bb0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5694\/mja11.10125","article-title":"Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation","volume":"195","author":"Olsen","year":"2011","journal-title":"Med. J. Aust."},{"issue":"2","key":"10.1016\/j.jprot.2018.09.018_bb0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/089583799197203","article-title":"Models for mesothelioma incidence following exposure to fibers in terms of timing and duration of exposure and the biopersistence of the fibers","volume":"11","author":"Berry","year":"1999","journal-title":"Inhal. Toxicol."},{"issue":"4","key":"10.1016\/j.jprot.2018.09.018_bb0040","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1136\/oem.2003.008128","article-title":"Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia","volume":"61","author":"Berry","year":"2004","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.jprot.2018.09.018_bb0045","series-title":"Dail and Hammar's Pulmonary Pathology: Volume II: Neoplastic Lung Disease","first-page":"558","article-title":"Neoplasms of the pleura","author":"Hammar","year":"2008"},{"issue":"17","key":"10.1016\/j.jprot.2018.09.018_bb0050","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1080\/15287394.2014.899171","article-title":"Early and delayed effects of naturally occurring asbestos on serum biomarkers of inflammation and metabolism","volume":"77","author":"Kodavanti","year":"2014","journal-title":"J. Toxic. Environ. Health A"},{"issue":"3","key":"10.1016\/j.jprot.2018.09.018_bb0055","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ajim.10047","article-title":"Malignant mesothelioma in Australia, 1945\u20132000","volume":"41","author":"Leigh","year":"2002","journal-title":"Am. J. Ind. Med."},{"issue":"2","key":"10.1016\/j.jprot.2018.09.018_bb0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/01913120252959227","article-title":"Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases","volume":"26","author":"Roggli","year":"2002","journal-title":"Ultrastruct. Pathol."},{"issue":"6","key":"10.1016\/j.jprot.2018.09.018_bb0065","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.jprot.2018.09.018_bb0070","series-title":"Pathology of Lung Tumors","first-page":"241","article-title":"Malignant mesothelioma of the pleura: current surgical pathology","author":"Henderson","year":"1997"},{"issue":"5","key":"10.1016\/j.jprot.2018.09.018_bb0075","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/JTO.0b013e318211127a","article-title":"Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma","volume":"6","author":"Kadota","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.jprot.2018.09.018_bb0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejcts.2007.09.044","article-title":"Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients","volume":"33","author":"Borasio","year":"2008","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.jprot.2018.09.018_bb0085","series-title":"Update on Malignant Pleural Mesothelioma, Seminars in Respiratory and Critical Care Medicine\u00a9","first-page":"102","author":"Campbell","year":"2011"},{"issue":"10","key":"10.1016\/j.jprot.2018.09.018_bb0090","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jclinpath-2012-201303","article-title":"Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers","volume":"66","author":"Henderson","year":"2013","journal-title":"J. Clin. Pathol."},{"issue":"9396","key":"10.1016\/j.jprot.2018.09.018_bb0095","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jprot.2018.09.018_bb0100","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin\u2013related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"17","key":"10.1016\/j.jprot.2018.09.018_bb0105","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jprot.2018.09.018_bb0110","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"15","key":"10.1016\/j.jprot.2018.09.018_bb0115","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jprot.2018.09.018_bb0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1515\/CCLM.2010.066","article-title":"Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels","volume":"48","author":"Rai","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"issue":"44","key":"10.1016\/j.jprot.2018.09.018_bb0125","doi-asserted-by":"crossref","first-page":"77872","DOI":"10.18632\/oncotarget.20845","article-title":"Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1","volume":"8","author":"Eguchi","year":"2017","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.jprot.2018.09.018_bb0130","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-0472","article-title":"Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma","volume":"12","author":"Onda","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"2B","key":"10.1016\/j.jprot.2018.09.018_bb0135","first-page":"599","article-title":"Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells","volume":"24","author":"Liu","year":"2004","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.jprot.2018.09.018_bb0140","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1074\/mcp.M113.030775","article-title":"Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma","volume":"13","author":"Mundt","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"issue":"15","key":"10.1016\/j.jprot.2018.09.018_bb0145","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jprot.2018.09.018_bb0150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/153303460900800502","article-title":"Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS","volume":"8","author":"Hegmans","year":"2009","journal-title":"Technol. Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.jprot.2018.09.018_bb0155","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1074\/mcp.M113.030775","article-title":"Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma","volume":"13","author":"Mundt","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"issue":"12","key":"10.1016\/j.jprot.2018.09.018_bb0160","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/nmeth.2702","article-title":"Mapping differential interactomes by affinity purification coupled with data-independent mass spectrometry acquisition","volume":"10","author":"Lambert","year":"2013","journal-title":"Nat. Methods"},{"issue":"11","key":"10.1016\/j.jprot.2018.09.018_bb0165","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/1097-0142(19831201)52:11<2151::AID-CNCR2820521129>3.0.CO;2-S","article-title":"Ratios of pleural fluid to serum immunoglobulins in malignant pleural effusions","volume":"52","author":"Desai","year":"1983","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jprot.2018.09.018_bb0170","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1165\/rcmb.2003-0238OC","article-title":"Proteomic analysis of exosomes isolated from human malignant pleural effusions","volume":"31","author":"Bard","year":"2004","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.jprot.2018.09.018_bb0175","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejso.2007.04.009","article-title":"A review of the S100 proteins in cancer","volume":"34","author":"Salama","year":"2008","journal-title":"Eur. J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.jprot.2018.09.018_bb0180","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.jprot.2018.09.018_bb0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/modpathol.3880483","article-title":"Expression of cytokeratin 5\/6 in epithelial neoplasms: an immunohistochemical study of 509 cases","volume":"15","author":"Chu","year":"2002","journal-title":"Mod. Pathol."},{"issue":"18","key":"10.1016\/j.jprot.2018.09.018_bb0190","first-page":"4376","article-title":"Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance","volume":"53","author":"Klominek","year":"1993","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.jprot.2018.09.018_bb0195","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrc1230","article-title":"The 14-3-3 cancer connection","volume":"3","author":"Hermeking","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.jprot.2018.09.018_bb0200","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/bies.1134","article-title":"14-3-3 proteins: key regulators of cell division, signalling and apoptosis","volume":"23","author":"van Hemert","year":"2001","journal-title":"BioEssays"},{"issue":"2","key":"10.1016\/j.jprot.2018.09.018_bb0205","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21873\/cgp.20023","article-title":"A proteomic analysis of the malignant mesothelioma secretome using iTRAQ","volume":"14","author":"Creaney","year":"2017","journal-title":"Cancer Genom. Proteom."},{"issue":"2","key":"10.1016\/j.jprot.2018.09.018_bb0210","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0169-5002(96)81604-7","article-title":"Inflammation in malignant pleural mesothelioma: Interleukin-6 (IL-6) and its relationship to serum parameters","volume":"15","author":"Nakano","year":"1996","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.jprot.2018.09.018_bb0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00428-001-0582-9","article-title":"Pathology, diagnosis and pathogenesis of AA amyloidosis","volume":"440","author":"R\u00f6cken","year":"2002","journal-title":"Virchows Arch."},{"issue":"2","key":"10.1016\/j.jprot.2018.09.018_bb0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0344-0338(00)80037-0","volume":"196","author":"Kayser","year":"2000","journal-title":"Pathol. Res. Pract."},{"issue":"3","key":"10.1016\/j.jprot.2018.09.018_bb0225","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of novel markers for the diagnosis of malignant pleural mesothelioma","volume":"178","author":"Gueugnon","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.jprot.2018.09.018_bb0230","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/JTO.0b013e31824c9272","article-title":"CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions","volume":"7","author":"Blanquart","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.jprot.2018.09.018_bb0235","first-page":"3080","article-title":"Gene expression profiling of malignant mesothelioma","volume":"9","author":"Singhal","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jprot.2018.09.018_bb0240","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.jprot.2018.09.018_bb0245","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.jprot.2018.09.018_bb0250","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ijc.10996","article-title":"Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops","volume":"104","author":"Masood","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.jprot.2018.09.018_bb0255","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jprot.2018.09.018_bb0260","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rmed.2010.10.010","article-title":"Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma","volume":"105","author":"Hirayama","year":"2011","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.jprot.2018.09.018_bb0265","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0002-9440(10)63739-X","article-title":"Proteomic analysis of exosomes secreted by human mesothelioma cells","volume":"164","author":"Hegmans","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"3\u20134","key":"10.1016\/j.jprot.2018.09.018_bb0270","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/prca.201300052","article-title":"Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear Lamin and filament-related proteins","volume":"8","author":"Giusti","year":"2014","journal-title":"Proteom. Clin. Appl."},{"issue":"2","key":"10.1016\/j.jprot.2018.09.018_bb0275","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0955-0674(98)80144-0","article-title":"Integrin signaling and cell growth control","volume":"10","author":"Howe","year":"1998","journal-title":"Curr. Opin. Cell Biol."},{"issue":"6","key":"10.1016\/j.jprot.2018.09.018_bb0280","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/(SICI)1097-0215(19970917)72:6<1034::AID-IJC19>3.0.CO;2-4","article-title":"Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins","volume":"72","author":"Klominek","year":"1997","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.jprot.2018.09.018_bb0285","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/JTO.0b013e31829ceb6a","article-title":"Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior","volume":"8","author":"Goparaju","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"43","key":"10.1016\/j.jprot.2018.09.018_bb0290","doi-asserted-by":"crossref","first-page":"69565","DOI":"10.18632\/oncotarget.11829","article-title":"Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"6C","key":"10.1016\/j.jprot.2018.09.018_bb0295","first-page":"4833","article-title":"Expression of vascular endothelial growth factor in malignant mesothelioma","volume":"26","author":"Aoe","year":"2006","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.jprot.2018.09.018_bb0300","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jprot.2018.09.018_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2018.02.026","article-title":"SWATH mass spectrometry as a tool for quantitative profiling of the matrisome","author":"Krasny","year":"2018","journal-title":"J. Proteome"},{"key":"10.1016\/j.jprot.2018.09.018_bb0310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12014-018-9201-5","article-title":"Comparison of iTRAQ and SWATH in a clinical study with multiple time points","volume":"15","author":"Jylha","year":"2018","journal-title":"Clin. Proteomics"},{"issue":"D1","key":"10.1016\/j.jprot.2018.09.018_bb0315","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gkv1145","article-title":"2016 update of the PRIDE database and its related tools","volume":"44","author":"Vizcaino","year":"2016","journal-title":"Nucleic Acids Res."}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391918303592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391918303592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T17:46:04Z","timestamp":1545068764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391918303592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":63,"alternative-id":["S1874391918303592"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2018.09.018","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jprot.2018.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}